Literature DB >> 6451692

Treatment complications of rheumatoid arthritis with gold, hydroxychloroquine, D-penicillamine, and levamisole.

Z Husain, L A Runge.   

Abstract

One hundred and twenty-five patients with active rheumatoid arthritis unresponsive to nonsteroidal antiinflammatory drugs were treated at the same center with 156 courses of either hydroxychloroquine (43), gold (29), D-penicillamine (40), or levamisole (44). Life table analysis was used to compare the risks of developing various side effects with treatment termination being the endpoint instead of death. Patients treated with levamisole had the highest risk of developing a complication (67%) and antimalarials the lowest (30%). In terms of long term acceptability, hydroxychloroquine showed fewer complications, gold and D-penicillamine were similar with rash and proteinuria being the main difficulties; however, levamisole caused the most frequent terminations mainly due to rash and leukopenia.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6451692

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  13 in total

Review 1.  Combination chemotherapy in rheumatoid arthritis.

Authors:  P M Brooks; A C Schwarzer
Journal:  Ann Rheum Dis       Date:  1991-07       Impact factor: 19.103

2.  A 10 year follow up of parenteral gold therapy in patients with rheumatoid arthritis.

Authors:  G Bendix; A Bjelle
Journal:  Ann Rheum Dis       Date:  1996-03       Impact factor: 19.103

3.  A prospective analysis of risk factors for the discontinuation of second-line antirheumatic drugs.

Authors:  M J Wijnands; M A Van 't Hof; M A Van Leeuwen; M H Van Rijswijk; L B Van de Putte; P L Van Riel
Journal:  Pharm World Sci       Date:  1993-10-15

4.  Does the order of second-line treatment in rheumatoid arthritis matter?

Authors:  M M Steven; J A Hunter; R M Murdoch; H A Capell
Journal:  Br Med J (Clin Res Ed)       Date:  1982-01-09

5.  Therapeutic workshop on modifying the disease process in rheumatoid arthritis: immunosuppression in perspective.

Authors: 
Journal:  Ann Rheum Dis       Date:  1982       Impact factor: 19.103

6.  Hydroxychloroquine sulphate in the treatment of rheumatoid arthritis: a double blind comparison of two dose regimens.

Authors:  K Pavelka; K P Sen; Z Pelísková; J Vácha; K Trnavský
Journal:  Ann Rheum Dis       Date:  1989-07       Impact factor: 19.103

Review 7.  Rational use of disease-modifying antirheumatic drugs.

Authors:  D E Furst
Journal:  Drugs       Date:  1990-01       Impact factor: 9.546

8.  Chloroquine in long-term treatment of rheumatoid arthritis.

Authors:  A Bjelle; A Björnham; A Larsen; T Mjörndal
Journal:  Clin Rheumatol       Date:  1983-12       Impact factor: 2.980

9.  Bioavailability of hydroxychloroquine tablets in healthy volunteers.

Authors:  S E Tett; D J Cutler; R O Day; K F Brown
Journal:  Br J Clin Pharmacol       Date:  1989-06       Impact factor: 4.335

10.  Continuation of long term treatment with hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis.

Authors:  E F Morand; P I McCloud; G O Littlejohn
Journal:  Ann Rheum Dis       Date:  1992-12       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.